Kaletra Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Alerts
• Clinical Trials
• Forums

Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Condition:   Acute Respiratory Distress Syndrome Interventions:   Drug: Wharton's jelly derived Mesenchymal stem cells.;   Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) Sponsors:   BioXcellerator;   Clinical Somer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 15, 2020 Category: Research Source Type: clinical trials